Auto Immun Highlights. 2018 Feb 12;9(1):3. doi: 10.1007/s13317-018-0102-4.
Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves' disease.
Auto- immunity highlights
Danilo Villalta, Federica D'Aurizio, Mirella Da Re, Debora Ricci, Francesco Latrofa, Renato Tozzoli
Affiliations
Affiliations
- Immunology and Allergy Unit, S. Maria degli Angeli Hospital, Pordenone, Italy. [email protected].
- Clinical Pathology Laboratory, University Hospital, Udine, Italy.
- Immunology and Allergy Unit, S. Maria degli Angeli Hospital, Pordenone, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Clinical Pathology Laboratory, S. Maria degli Angeli Hospital, Pordenone, Italy.
PMID: 29435670
PMCID: PMC5809681 DOI: 10.1007/s13317-018-0102-4
Abstract
PURPOSE: Thyrotropin receptor (TSHR) autoantibodies (TRAbs) are a hallmark of Graves' disease (GD). The aim of this study was to evaluate the diagnostic accuracy of a new third generation automatic fluorescence enzyme immunoassay for TRAb measurement in GD, in comparison with two current IMAs.
METHODS: Sera of 439 subjects (57 patients with untreated GD, 34 with treated GD, 15 with GD and Graves' orbitopathy, 52 with multinodular non-toxic goiter, 86 with Hashimoto's thyroiditis, 20 with toxic adenoma or toxic multinodular goiter, 55 with non-thyroid autoimmune diseases and 120 normal controls) were tested for TRAbs with the ELiA
RESULTS: Sensitivity and specificity of the ELiA™ anti-TSH-R assay, TRAK™ RIA and Immulite™ TSI assay were 94.7% and 99.6, 100 and 98.2%, 100 and 98.2%, respectively. Spearman's coefficient and Passing-Bablok regression showed a satisfactory correlation between EliA™ and TRAK™ [rho: 0.925; 95% CI: 0.883-0-953. Intercept: - 0.875 (95% CI: - 2.411 to 0.194); slope: 1.086 (95% CI: 0.941 to 1.248)], and between ELiA
CONCLUSIONS: The diagnostic performance of ELiA
Keywords: ELiA™ anti-TSH-R assay; Graves’ disease (GD); Immunometric assays; Thyrotropin receptor autoantibodies (TRAbs)
References
- J Clin Invest. 2002 Jul;110(2):209-17 - PubMed
- Thyroid. 2003 Jan;13(1):3-126 - PubMed
- J Clin Invest. 2003 Jun;111(12):1897-904 - PubMed
- J Clin Pathol. 2004 Apr;57(4):378-82 - PubMed
- J Endocrinol Invest. 2004 Mar;27(3):216-20 - PubMed
- J Clin Endocrinol Metab. 2004 Sep;89(9):4734-45 - PubMed
- J Clin Invest. 2005 Aug;115(8):1972-83 - PubMed
- Biochem Biophys Res Commun. 2010 Mar 12;393(3):526-30 - PubMed
- Rheumatol Int. 2012 Jan;32(1):73-8 - PubMed
- Endocr Pract. 2011 May-Jun;17(3):456-520 - PubMed
- J Thyroid Res. 2012;2012:182176 - PubMed
- Autoimmun Rev. 2012 Dec;12(2):107-13 - PubMed
- Thyroid. 2013 Jan;23(1):14-24 - PubMed
- Autoimmun Rev. 2015 Jan;14(1):75-9 - PubMed
- Eur Thyroid J. 2015 Mar;4(1):3-5 - PubMed
- Horm Metab Res. 2015 Nov;47(12):880-8 - PubMed
- Horm Metab Res. 2015 Sep;47(10):727-34 - PubMed
- Horm Metab Res. 2015 Sep;47(10):735-52 - PubMed
- Clin Chem Lab Med. 2017 Jan 1;55(1):58-64 - PubMed
- Thyroid. 2016 Oct;26(10):1343-1421 - PubMed
- Horm Metab Res. 2016 Dec;48(12):795-801 - PubMed
- Lancet. 1974 Aug 24;2(7878):427-31 - PubMed
- Clin Chem. 1993 Apr;39(4):561-77 - PubMed
- J Clin Endocrinol Metab. 1998 Jan;83(1):40-6 - PubMed
- Endocr Rev. 1998 Dec;19(6):673-716 - PubMed
Publication Types